News
12-12-2008, 10:13 AM
New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.[i] In the study, women diagnosed with post-menopausal, hormone receptor positive (HR+) and ErbB2 positive metastatic breast cancer experienced a 5.
More... (http://www.medicalnewstoday.com/articles/132882.php)
More... (http://www.medicalnewstoday.com/articles/132882.php)